Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

Farrukh T. Awan, Neil Elliot Kay, Melanie E. Davis, Wenting Wu, Susan M. Geyer, Nelson Leung, Diane F Jelinek, Renee C. Tschumper, Charla R. Secreto, Thomas S. Lin, Michael R. Grever, Tait D. Shanafelt, Clive S. Zent, Timothy G. Call, Nyla A. Heerema, Gerard Lozanski, John C. Byrd, David M. Lucas

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic member of the Bcl-2 protein family. Increased Mcl-1 expression is associated with failure to achieve remission after treatment with fludarabine and chlorambucil in patients with chronic lymphocytic leukemia (CLL). However, the influence of Mcl-1 expression has not been examined in CLL trials using chemoimmunotherapy. We investigated Mcl-1 protein expression prospectively as part of a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients with untreated CLL. No significant difference by Mcl-1 expression was noted in pretreatment or response parameters. However, in patients with higher Mcl-1 expression, both minimal residual disease-negative status and progression-free survival was found to be significantly reduced (57% vs 19%, P = .01; 50.8 vs 18.7 months; P = .02; respectively). Mcl-1 expression may therefore be useful in predicting poor response to chemoimmunotherapy. These findings further support pursuing treatment strategies targeting this important antiapoptotic protein. (Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.)

Original languageEnglish (US)
Pages (from-to)535-537
Number of pages3
JournalBlood
Volume113
Issue number3
DOIs
StatePublished - Jan 15 2009

Fingerprint

Pentostatin
Myeloid Leukemia
Myeloid Cells
B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Disease-Free Survival
Chlorambucil
Proteins
Residual Neoplasm
Rituximab
Clinical Trials
Databases
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. / Awan, Farrukh T.; Kay, Neil Elliot; Davis, Melanie E.; Wu, Wenting; Geyer, Susan M.; Leung, Nelson; Jelinek, Diane F; Tschumper, Renee C.; Secreto, Charla R.; Lin, Thomas S.; Grever, Michael R.; Shanafelt, Tait D.; Zent, Clive S.; Call, Timothy G.; Heerema, Nyla A.; Lozanski, Gerard; Byrd, John C.; Lucas, David M.

In: Blood, Vol. 113, No. 3, 15.01.2009, p. 535-537.

Research output: Contribution to journalArticle

Awan, FT, Kay, NE, Davis, ME, Wu, W, Geyer, SM, Leung, N, Jelinek, DF, Tschumper, RC, Secreto, CR, Lin, TS, Grever, MR, Shanafelt, TD, Zent, CS, Call, TG, Heerema, NA, Lozanski, G, Byrd, JC & Lucas, DM 2009, 'Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab', Blood, vol. 113, no. 3, pp. 535-537. https://doi.org/10.1182/blood-2008-08-173450
Awan, Farrukh T. ; Kay, Neil Elliot ; Davis, Melanie E. ; Wu, Wenting ; Geyer, Susan M. ; Leung, Nelson ; Jelinek, Diane F ; Tschumper, Renee C. ; Secreto, Charla R. ; Lin, Thomas S. ; Grever, Michael R. ; Shanafelt, Tait D. ; Zent, Clive S. ; Call, Timothy G. ; Heerema, Nyla A. ; Lozanski, Gerard ; Byrd, John C. ; Lucas, David M. / Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. In: Blood. 2009 ; Vol. 113, No. 3. pp. 535-537.
@article{49bd29bdf459492ca96ccde0e484d36c,
title = "Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab",
abstract = "Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic member of the Bcl-2 protein family. Increased Mcl-1 expression is associated with failure to achieve remission after treatment with fludarabine and chlorambucil in patients with chronic lymphocytic leukemia (CLL). However, the influence of Mcl-1 expression has not been examined in CLL trials using chemoimmunotherapy. We investigated Mcl-1 protein expression prospectively as part of a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients with untreated CLL. No significant difference by Mcl-1 expression was noted in pretreatment or response parameters. However, in patients with higher Mcl-1 expression, both minimal residual disease-negative status and progression-free survival was found to be significantly reduced (57{\%} vs 19{\%}, P = .01; 50.8 vs 18.7 months; P = .02; respectively). Mcl-1 expression may therefore be useful in predicting poor response to chemoimmunotherapy. These findings further support pursuing treatment strategies targeting this important antiapoptotic protein. (Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.)",
author = "Awan, {Farrukh T.} and Kay, {Neil Elliot} and Davis, {Melanie E.} and Wenting Wu and Geyer, {Susan M.} and Nelson Leung and Jelinek, {Diane F} and Tschumper, {Renee C.} and Secreto, {Charla R.} and Lin, {Thomas S.} and Grever, {Michael R.} and Shanafelt, {Tait D.} and Zent, {Clive S.} and Call, {Timothy G.} and Heerema, {Nyla A.} and Gerard Lozanski and Byrd, {John C.} and Lucas, {David M.}",
year = "2009",
month = "1",
day = "15",
doi = "10.1182/blood-2008-08-173450",
language = "English (US)",
volume = "113",
pages = "535--537",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

AU - Awan, Farrukh T.

AU - Kay, Neil Elliot

AU - Davis, Melanie E.

AU - Wu, Wenting

AU - Geyer, Susan M.

AU - Leung, Nelson

AU - Jelinek, Diane F

AU - Tschumper, Renee C.

AU - Secreto, Charla R.

AU - Lin, Thomas S.

AU - Grever, Michael R.

AU - Shanafelt, Tait D.

AU - Zent, Clive S.

AU - Call, Timothy G.

AU - Heerema, Nyla A.

AU - Lozanski, Gerard

AU - Byrd, John C.

AU - Lucas, David M.

PY - 2009/1/15

Y1 - 2009/1/15

N2 - Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic member of the Bcl-2 protein family. Increased Mcl-1 expression is associated with failure to achieve remission after treatment with fludarabine and chlorambucil in patients with chronic lymphocytic leukemia (CLL). However, the influence of Mcl-1 expression has not been examined in CLL trials using chemoimmunotherapy. We investigated Mcl-1 protein expression prospectively as part of a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients with untreated CLL. No significant difference by Mcl-1 expression was noted in pretreatment or response parameters. However, in patients with higher Mcl-1 expression, both minimal residual disease-negative status and progression-free survival was found to be significantly reduced (57% vs 19%, P = .01; 50.8 vs 18.7 months; P = .02; respectively). Mcl-1 expression may therefore be useful in predicting poor response to chemoimmunotherapy. These findings further support pursuing treatment strategies targeting this important antiapoptotic protein. (Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.)

AB - Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic member of the Bcl-2 protein family. Increased Mcl-1 expression is associated with failure to achieve remission after treatment with fludarabine and chlorambucil in patients with chronic lymphocytic leukemia (CLL). However, the influence of Mcl-1 expression has not been examined in CLL trials using chemoimmunotherapy. We investigated Mcl-1 protein expression prospectively as part of a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients with untreated CLL. No significant difference by Mcl-1 expression was noted in pretreatment or response parameters. However, in patients with higher Mcl-1 expression, both minimal residual disease-negative status and progression-free survival was found to be significantly reduced (57% vs 19%, P = .01; 50.8 vs 18.7 months; P = .02; respectively). Mcl-1 expression may therefore be useful in predicting poor response to chemoimmunotherapy. These findings further support pursuing treatment strategies targeting this important antiapoptotic protein. (Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.)

UR - http://www.scopus.com/inward/record.url?scp=60249088881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249088881&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-08-173450

DO - 10.1182/blood-2008-08-173450

M3 - Article

VL - 113

SP - 535

EP - 537

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -